Editorial: Gastrointestinal cancer immune response and immune related adverse effects

Editorial: Gastrointestinal cancer immune response and immune related adverse effects

Bibliographic Details
Main Authors:	Ti Wen, Yanhong Deng, Bo Qin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Oncology
Subjects:	immune response GI cancers immune related adverse effects tumor microenvironment biomarker
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1034890/full

Similar Items

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Editorial: Mutational signatures and immune response in cancer
by: Ilias Georgakopoulos-Soares, et al.
Published: (2023-05-01)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
by: Yanni Wang, et al.
Published: (2022-09-01)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
by: Iñigo Les, et al.
Published: (2023-03-01)

Advances in Predictive Research of Immune Checkpoint Inhibitors-related  Adverse Events
by: Jing ZHANG, et al.
Published: (2023-10-01)

The current understanding of the immune landscape relative to radiotherapy across tumor types
by: Chrysanthi Iliadi, et al.
Published: (2023-03-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy
by: Lei Zhang, et al.
Published: (2022-11-01)

Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors
by: Xiaoying Li, et al.
Published: (2021-10-01)

Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
by: Elisa Giommoni, et al.
Published: (2021-08-01)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
by: Akhil Kapoor, et al.
Published: (2022-10-01)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
by: Kennedy Yao Yi Ng, et al.
Published: (2021-10-01)

Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study
by: Yoshihiko Tasaki, et al.
Published: (2023-12-01)

Editorial: Cell network in antitumor immunity of pediatric and adult solid tumors
by: Silvia Pesce, et al.
Published: (2023-07-01)

Immune related biomarkers for cancer metastasis to the brain
by: Wei-Wei Chen, et al.
Published: (2022-12-01)

TRIM56: a promising prognostic immune biomarker for glioma revealed by pan-cancer and single-cell analysis
by: Bingcheng Wang, et al.
Published: (2024-01-01)

Laboratory biomarkers of an effective antitumor immune response. Clinical significance.
by: A.M. Malkova, et al.
Published: (2021-01-01)

Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
by: Katharina Leucht, et al.
Published: (2022-09-01)

Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
by: Manabu Yasuda, et al.
Published: (2022-09-01)

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
by: Junyu Long, et al.
Published: (2022-02-01)

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report
by: Takaaki Arigami, et al.
Published: (2020-10-01)

Tumor immune microenvironment (TIME) to enhance antitumor immunity
by: Sajin Rajbhandary, et al.
Published: (2023-05-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
by: Terufumi Kubo, et al.
Published: (2021-09-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
by: Ting Cao, et al.
Published: (2023-06-01)

Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments
by: Xiangyan Wu, et al.
Published: (2020-01-01)

Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma
by: Mykhaylo Usyk, et al.
Published: (2021-10-01)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
by: Busra Isik, et al.
Published: (2021-04-01)

An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer
by: Kaibo Zhu, et al.
Published: (2024-01-01)

Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
by: Ying Zhang, et al.
Published: (2022-01-01)

Identification of Immune-Related Genes for Establishment of Prognostic Index in Hepatocellular Carcinoma
by: Yinfang Li, et al.
Published: (2021-11-01)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
by: Anca Bobircă, et al.
Published: (2021-06-01)

Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors
by: Zhening Zhang, et al.
Published: (2022-07-01)

Immune-related adverse events of immune checkpoint inhibitors: a review
by: Qinan Yin, et al.
Published: (2023-05-01)

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
by: Adithya Chennamadhavuni, et al.
Published: (2022-04-01)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
by: Ana Cardeña-Gutiérrez, et al.
Published: (2022-06-01)

Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study
by: Xiaoxiao Ge, et al.
Published: (2023-09-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity
by: Bassam Janji, et al.
Published: (2018-04-01)